Skip to content
10-K

Annual Report

Evommune, Inc. EVMN

0001193125-26-093932

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 3, 2026 36.02M sh
Shares Diluted FY 2025 · Dec 31, 2025 6.14M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.51M sh
Capex FY 2025 · Dec 31, 2025 $235K
Capex FY 2025 · Dec 31, 2024 $88K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$76.44M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$58.2M
Short Term Investments FY 2025 · Dec 31, 2025 $105.14M
Short Term Investments FY 2025 · Dec 31, 2024 $55.79M
Cash And Equivalents FY 2025 · Dec 31, 2025 $44.06M
Cash And Equivalents FY 2025 · Dec 31, 2024 $16.26M
Stockholders Equity FY 2025 · Dec 31, 2025 $205.57M
Stockholders Equity FY 2025 · Dec 31, 2024 −$144.24M
Stockholders Equity FY 2025 · Dec 31, 2023 −$77.71M
Current Liabilities FY 2025 · Dec 31, 2025 $17.91M
Current Liabilities FY 2025 · Dec 31, 2024 $27.98M
Total Liabilities FY 2025 · Dec 31, 2025 $19.38M
Total Liabilities FY 2025 · Dec 31, 2024 $28.52M
Current Assets FY 2025 · Dec 31, 2025 $153.48M
Current Assets FY 2025 · Dec 31, 2024 $73.99M
Total Assets FY 2025 · Dec 31, 2025 $224.95M
Total Assets FY 2025 · Dec 31, 2024 $76.06M
Eps Diluted FY 2025 · Dec 31, 2025 −$11.22
Eps Diluted FY 2025 · Dec 31, 2024 −$45.29
Eps Basic FY 2025 · Dec 31, 2025 −$11.22
Eps Basic FY 2025 · Dec 31, 2024 −$45.29
Sga Expense FY 2025 · Dec 31, 2025 $20.03M
Sga Expense FY 2025 · Dec 31, 2024 $12.77M
Rd Expense FY 2025 · Dec 31, 2025 $74.04M
Rd Expense FY 2025 · Dec 31, 2024 $64.24M
Net Income FY 2025 · Dec 31, 2025 −$68.87M
Net Income FY 2025 · Dec 31, 2024 −$66.81M
Operating Income FY 2025 · Dec 31, 2025 −$81.07M
Operating Income FY 2025 · Dec 31, 2024 −$70.01M
Revenue FY 2025 · Dec 31, 2025 $13M
Revenue FY 2025 · Dec 31, 2024 $7M